-
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Matthews
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Morehead City
-
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582 ·
Phase: Phase 3 ·
Ages: 55 Years and older ·
Sex: All (male and female)
· North Carolina: Monroe
-
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768 ·
Phase: Phase 1 ·
Ages: 45 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578 ·
Phase: Phase 3 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Greensboro
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106 ·
Phase: Phase 1, Phase 2 ·
Ages: 35 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Matthews
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female)
· North Carolina: Raleigh
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833 ·
Phase: Phase 2 ·
Ages: 55 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Greensboro, Matthews, Morehead City, Shelby
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216 ·
Phase: Phase 3 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Matthews
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Morehead City
-
ADRC Clinical Cohort (Alzheimer's Disease)
NCT06703541 ·
Phase: Not specified ·
Ages: 25 Years to 80 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
Cereset Research for Caregivers
NCT05209438 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
Connect-Home: Alzheimer's Disease and Related Dementias
NCT06840587 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 19 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
NCT07701161 ·
Phase: Not specified ·
Ages: 40 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
NCT06041789 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Improving PCP Advance Care Planning for People With ADRD
NCT06565169 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Inspiring Seniors Towards Exercise Promotion to Protect Cognition
NCT06496425 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 65 Years and older ·
Sex: All (male and female)
· North Carolina: Greensboro
-
Late Onset Alzheimer's Disease
NCT05010603 ·
Phase: Not specified ·
Ages: 55 Years and older ·
Sex: All (male and female)
· North Carolina: Raleigh
-
Olfactory Biopsies
NCT07021040 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Greensboro, Matthews, Morehead City, Shelby
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709 ·
Phase: Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female)
· North Carolina: Matthews
-
Physical Activity and Community EmPOWERment Project
NCT06740162 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Retinal Imaging in Neurodegenerative Disease
NCT03233646 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352 ·
Phase: Phase 3 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Greensboro
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984 ·
Phase: Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Raleigh
-
Wake Forest Alzheimer's Disease Clinical Core
NCT03140865 ·
Phase: Not specified ·
Ages: 55 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·
Phase: Phase 3 ·
Ages: 50 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte